Posted by Michael Wonder on 11 Oct 2022
The China NMPA approved Cyramza (ramucirumab) for the treatment in patients with hepatocellular carcinoma
9 October 2022 - Innovent Biologics is pleased to see that the NMPA of China has approved the supplemental new drug application for Cyramza (ramucirumab) in patients with hepatocellular carcinoma, who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
In March 2022, Cyramza (ramucirumab) was approved by the NMPA in combination with paclitaxel for second-line treatment in patients with advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma, making it the first and only targeted drug approved for the second-line treatment of advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma in China.
